• Prescribing Information
  • Medical Information
  • Patient Site
  • Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.

    Click here to learn how we are responding.

    Broad pneumococcal defense1

    Prevnar 20™ helps protect against the 20 Streptococcus pneumoniae serotypes in the vaccine1-3

    A new level of protection from a pneumococcal conjugate vaccine1

    Building on the efficacy of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein)] with 7 additional serotypes, Prevnar 20™ delivers the most serotypes from a pneumococcal conjugate vaccine.1-3

    Discover broad conjugate coverage

    A new level of protection

    With the most serotypes in a pneumococcal conjugate vaccine, you 
    can help protect your patients from 
    more disease.1,2,4,5

    See the coverage difference

    ** This is an optional area where footnotes can live.

    Studied across adult populations

    Prevnar 20™ demonstrated immunogenicity in pneumococcal vaccine-naïve and previously vaccinated adults.1

    Evaluate the studies

    ** This is an optional area where footnotes can live.

    Built on an established vaccine

    Prevnar 20™ was designed to expand on the efficacy of Prevnar 13®.1

    Editable Link Text
    Review the data

    ** This is an optional area where footnotes can live.



    ​​​​​​​
    ​​​​​​​

    References: 1. Prevnar 20™ (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information, Wyeth Pharmaceuticals LLC, 2021. 2. Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) Prescribing Information, Wyeth Pharmaceuticals LLC, 2019. 3. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-1125. 4. Poehling K, Kobayashi M for the Pneumococcal Work Group. Introduction of the Pneumococcal Work Group. Presented at: Advisory Committee on Immunization Practices; October 28, 2020. Accessed February 5, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-10/pneumo-01-Poehling-Kobayashi-508.pdf 5. Grant LR, Ramirez J, Self WH, et al. Streptococcus pneumoniae Serotype Distribution and Coverage of Pneumococcal Conjugate Vaccines in Adults Hospitalized with Community-Acquired Pneumonia in the United States. ISPPD. 2020; abstract #879. Accessed February 5, 2021. https://cslide.ctimeetingtech.com/isppd20/attendee/confcal/presentation/list?q=grant 

    This site is intended only for US residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

    ​​​​​Manufactured by Wyeth Pharmaceuticals LLC.
    © 2021 Pfizer Inc.

    ​​​​​​​​​​​​All rights reserved.

    Marketed by Pfizer Inc.
    July 2021

    ​​​​​Manufactured by Wyeth Pharmaceuticals LLC.
    ​​​​​​​Marketed by Pfizer Inc.
    © 2021 Pfizer Inc. ​​​​​​​​​​​​All rights reserved. July 2021

    Indication

    • Prevnar 20™ is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older
    • This indication for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial 
      ​​​​​​​
      • Severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar 20™, Prevnar 13®, or to diphtheria toxoid is a contraindication
      • Safety and immunogenicity data on Prevnar 20™ are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20™
      • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response to Prevnar 13®
      • For Prevnar 20™, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in adults 18 through 59 years of age 
      • For Prevnar 13®, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>5%) were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash 

      Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

      Please click for Prevnar 20™ Full Prescribing Information.

      Please click for Prevnar 13® Full Prescribing Information.


      • Prevnar 20™ is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older 
      • The indication of Prevnar 20™ for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial 
      • Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older

      Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine